Jackson Creek Investment Advisors LLC Takes Position in Medpace Holdings, Inc. $MEDP

Jackson Creek Investment Advisors LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, HoldingsChannel reports. The fund acquired 2,290 shares of the company’s stock, valued at approximately $1,286,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. BOKF NA boosted its stake in shares of Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after purchasing an additional 20 shares in the last quarter. Valeo Financial Advisors LLC grew its stake in Medpace by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after purchasing an additional 21 shares during the last quarter. HighPoint Advisor Group LLC grew its stake in Medpace by 2.8% in the third quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares during the last quarter. Kaufman Rossin Wealth LLC grew its stake in Medpace by 3.4% in the fourth quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock valued at $447,000 after purchasing an additional 26 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after purchasing an additional 27 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Price Performance

Shares of MEDP stock opened at $428.00 on Thursday. Medpace Holdings, Inc. has a 1-year low of $291.28 and a 1-year high of $628.92. The stock’s fifty day moving average price is $457.76 and its 200 day moving average price is $515.44. The company has a market cap of $12.22 billion, a price-to-earnings ratio of 26.90, a price-to-earnings-growth ratio of 2.18 and a beta of 1.19.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business’s quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter last year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Several firms, including Rosen, Glancy Prongay, Levi & Korsinsky, Schall, Pomerantz, and others, issued reminders about the ongoing class action and the June 8 lead-plaintiff deadline, keeping legal overhang front and center for shareholders. Article Title
• Negative Sentiment: One lawsuit notice specifically highlights allegations that Medpace misled investors about cancellation rates and book-to-bill ratio, and references a prior 16% stock drop tied to those disclosures, reinforcing fears of further liability or reputational damage. Article Title
• Neutral Sentiment: Zacks published a comparison of Medpace versus Labcorp on valuation, which may influence investor sentiment only modestly and does not appear to be a major stock-moving catalyst. Article Title

Insider Activity

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on MEDP shares. Royal Bank Of Canada lowered their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Mizuho set a $582.00 target price on shares of Medpace in a research note on Wednesday, February 11th. Robert W. Baird cut their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Weiss Ratings lowered shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Finally, Leerink Partners cut their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $467.08.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.